Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Harvard Business School
Dow
Express Scripts
AstraZeneca

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,258,132

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,258,132 protect, and when does it expire?

Patent 8,258,132 protects EMEND and is included in two NDAs.

This patent has forty-eight patent family members in thirty-seven countries.

Summary for Patent: 8,258,132
Title:Pharmaceutical composition of a tachykinin receptor antagonist
Abstract: The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phen- yl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.
Inventor(s): Bosch; H. William (Bryn Mawr, PA), Liversidge; Elaine (West Chester, PA), Shelukar; Suhas D. (Lansdale, PA), Thompson; Karen C. (Lansdale, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:10/317,948
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,258,132

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No   Start Trial   Start Trial Y FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY   Start Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No   Start Trial   Start Trial Y PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING   Start Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No   Start Trial   Start Trial Y PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING   Start Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No   Start Trial   Start Trial Y FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Johnson and Johnson
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.